Why the study?
Does pretreatment with targeted pulmonary arterial hypertension therapy improve operability in adults with congenital heart disease and secondary pulmonary arterial hypertension?
Does pretreatment with targeted pulmonary arterial hypertension therapy improve operability in adults with congenital heart disease and secondary pulmonary arterial hypertension?
This paper discusses the evaluation of operability and the potential role of targeted PAH therapy in adults with congenital heart disease complicated by pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Caution advised on targeted PAH therapy for operability in adult CHD-PAH; leaves open need for prospective trials.
Despite recent advances in cardiac surgery that have allowed repair of congenital heart defects at a very young age, pulmonary arterial hypertension (PAH) secondary to congenital heart disease (CHD) remains a major problem. In its most severe form, the Eisenmenger syndrome, PAH and its complications result in a significant increase in morbidity and mortality and also greatly affect the quality of life of patients.
No takes yet. Share an insight, caveat, or question.
Dimopoulos et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: